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Sllmmal-y 
From a human histocompatibility leukocyte antigen (HLA)-DR/DQ hemizygous, B lympho- 
blastoid progenitor, we isolated a cell line, 10.24.6, with a DRoe missense mutation (96P~96S), 
which results in an N-linked carbohydrate addition at position 94 in the DRc~2 domain. Several 
features of 10.24.6 cells suggest that the mutation disrupts  normal intracellular  formation of 
peptide/DR complexes. The mutant HLA-DR dimers, though expressed at the cell surface, lack 
the conformation of the mature, peptide-loaded class II molecules of the progenitor cell, as assessed 
by their loss of binding of certain antibodies and by the lack of stability in detergent (sodium 
dodecyl sulfate) solution. In addition, presentation ofendocytosed antigen to HLA-DR-restricted 
T cells is defective in the mutant, but can be restored by transfection of a wild type DRA gene. 
Assays with synthetic peptides indicate that the 10.24.6 phenotype is not due to an intrinsic 
inability of the mutant DR molecules to bind peptides. Therefore,  to directly evaluate peptide 
occupancy of the mutant molecules, we analyzed add-eluted, HLA-DR-associated peptides. The 
predominant spedes from the 10.24.6 mutant is a nested set ofinvariant chain (Ii)-derived peptides 
that are undetectable  in the DR eluate from progenitor cells. The region of DRc~ altered in 
the mutant molecules is thus implicated in normal formation ofpeptide/DR complexes. Further, 
the same set of Ii peptides associated with the DR molecules is present in the eluate from an 
antigen presentation mutant with a defect in an major histocompatibility complex (MHC)-linked 
gene. These results suggest that DR. molecules in 10.24.6 and in certain presentation  mutants 
are affected at the same or related steps in class II molecule biosynthesis, raising the possibility 
that  class II molecules  interact  with  an  MHC-encoded accessory molecule during antigen 
presentation. 
C 
lass II MHC molecules are heterodimeric (ot/~) trans- 
membrane glycoproteins. They are expressed at the sur- 
face of antigen-presenting  cells (macrophages, dendritic cells, 
B cells), where they present bound peptides for surveillance 
by CD4 + T  cells. Peptides that become bound to class II 
molecules are generated by processing events within the en- 
docytic pathway, and the predominant class II-associated pep- 
tides derive from membrane and extracellular proteins (1, 2). 
Detection of peptide/dass II molecule complexes with specific 
T cells suggests that some peptides derived from other sources 
also become associated with class II molecules (3, 4). 
The formation of intracellular complexes between MHC 
class II molecules and peptides is a regulated process. One 
molecule involved is the invariant chain (Ii), which associates 
with nascent class II molecules and mediates their localiza- 
tion to endocytic compartments through a sequence in its 
cytoplasmic tail (5, 6).  Ii cleavage and dissociation  are ap- 
parent prerequisites for class II molecule/peptide binding (7). 
Expression of the p41 form of Ii, which has an alternatively 
spliced intraluminal portion, increases efficiency of presenta- 
tion of certain antigens,  perhaps by further modulation of 
dass II molecule trafficking (8). A second regulatory mole- 
cule  is  implied by  data  from  mutant  B  lymphoblastoid 
(B-LCL)  1 cell lines that are defective in dass  II-restricted 
antigen presentation,  but express normal levels of both in- 
variant chain and class II molecules (9). The defect in these 
1 Abbreviations used in this paper: B-LCL, B-lymphoblastoid;  C2P-1, class 
II presentation locus; HBsAg, hepatitis B surface antigen; MOMP, major 
outer membrane  protein;  PPD,  purified protein  derivative; TT, tetanus 
toxoid. 
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plexes from endocytosed proteins, resulting in deficient pre- 
sentation of intact protein antigens (though not of synthetic 
peptides)  and in altered  conformation of class II molecules 
expressed at the cell surface. The gene responsible  for this 
phenotype  (hereafter  called  "class  II  presentation  locus" 
[C2P-1])  maps to the MHC (10-12),  but its identity and 
specific function are unknown. 
Analyses of the relationship of fine structure to function 
in MHC class II molecules have delineated regions or residues 
involved in T cell receptor recognition (summarized in refer- 
ence 13), peptide binding (13, 14), interaction with the CD4 
molecule (15, 16), and most recently, dass II dimer-dimer 
interactions (14). However, regions of MHC class II mole- 
cules  specifically related to peptide loading have not been 
mapped.  To  elucidate  structure-function relationships  in 
human class II molecules, we have isolated informative mu- 
tant B-LCLs (17, 18). Here,  we describe  a  novel  B-LCL, 
10.24.6, in which HLA-DR molecules with an a2 domain 
mutation fail to become appropriately loaded with naturally 
processed  peptides, even though the mutant molecules are 
capable of binding DR-restricted peptides in vitro and the 
class II molecule loading pathway is intact in the cells. Our 
findings indicate that normal intracellular formation of pep- 
tide/HLA-DR complexes involves the region of the DR mol- 
ecule altered by the 10.24.6 mutation. Further, as the pheno- 
type of the mutant DR molecules resembles  that of DR 
molecules in a C2P-1 mutant derived from the same progen- 
itor, our findings suggest that class II molecules and the C2P-1 
regulatory protein may directly interact. 
Materials and Methods 
Antigen-presenting Cell Lines.  The progenitor cell line, 8.1.6, 
is a DR/DQ hemizygous B-LCL that expresses the HLA class II 
specificities DR3, DRw52a, DQ2,  and DP4.1, DP4.1 (reference 
17). To derive mutant 10.24.6, a young clone of 8.1.6 was mutage- 
nized with ethyl methane sulfonate  and immunoselected  with mAb 
16.23 plus complement, as described (see reference 17 for details). 
Mutants 9.5.3, 9.10.3, and 10.53.6 are C2P-l-defective  mutants (see 
text),  which  were also derived from  progenitor  8.1.6 by im- 
munoselection with mAb 16.23; the phenotypic characteristics of 
these mutants have been previously described in detail (9). 9.22.3 
is a DR-null B-LCL, derived from 8.1.6 by ddetion of the single 
DRA gene in 8.1.6 (reference 17); 9.22.3 retains expression of 
HLA-DQ and -DP molecules and presents DQ- and DP-restricted 
antigens normally (19). To generate the 10.24.6 x  9.22.3 hybrid, 
dominant  sdectable markers were introduced  into  9.22.3 and 
10.24.6. An  Escherichia coli gpt  gene, conferring  resistance to 
mycophenolic  acid, was transferred into 9.22.3 by electroporation 
as described (20). The dihydrofolate  reductase gene, conferring re- 
sistance to methotrexate, was introduced into 10.24.6 by coculture 
with PA317-SDHT, a retrovirus packaging fibroblast  line, provided 
by A. Dusty Miller, Fred Hutchinson Cancer Research Center, 
Seattle, WA. Somatic cell hybrids were prepared by polyethylene 
glycol  (PEG) fusion, as described  (9). For generation of the 10.24.6- 
DRA  transfectant,  10.24.6 was  cocultured  with PA317LHC- 
DILAc6, a retrovirus packaging fibroblast  line containing the DILA 
cDNA and the hygromycin phosphoribosyl transferase gene (21); 
this cell line was generously provided by William Kwok, Virginia 
Mason Research Center, Seattle, WA. Transferred  10.24.6 cells  were 
selected  in 100 ~g/ml hygromycin  B (Sigma  Chemical  Co., St. Louis, 
MO) and cloned in soft agar. 
T Cells and T Cell Proliferation Assays.  The DR3-restricted T 
cell clone specific for residues 241-265 of the major outer mem- 
brane protein (MOMP) of Chlamydia trachomatis was isolated as 
described (Barbosa,  J., manuscript submitted for publication) and 
kindly provided by Dr. James Barbosa, Miles, Inc., West Haven, 
CT. The other antigen-specific  T cell clones and lines were isolated 
and characterized as described (9, 19). The alloreactive, anti-DR3 
clone was isolated as described  (22) and was the gift of  Dr. Armead 
Johnson, Georgetown University, Washington, DC. The alloreac- 
tire, anti-DQ2 done (Cotner, T., unpublished results) was the gift 
of Dr. Tom Corner, University of Washington, Seattle, WA. The 
alloreactive, anti-DP4 T cells were isolated as described (23) and 
were kindly provided  by Susan Masewicz, Fred Hutchinson Cancer 
Research Center. None of the alloreactive  cell lines respond nor- 
mally to 8.1.6-derived, presentation defective (C2P-1) mutants as 
stimulators (24 and Mellins, E., unpublished results). For assay, 
2  x  104 T cell blasts were cocultured with 10  s mitocyin-C-treated 
B-LCL  as antigen-presenting  cells  or stimuhtors. For antigen-specific 
T cells, assays  were  performed in the presence or absence of either 
native antigen or immunogenic peptide. Protein antigens purified 
protein derivative  (PPD), tetanus toxoid (TT), and hepatitis B sur- 
face antigen (HBsAg) were used at 10/~g/ml, as described (9, 17). 
Recombinant  I-IBaAg  was the gift of  Merck, Sharp, & Dohme (West 
Point, PA). Synthetic peptides (MOMP 241-265, and TT 1274- 
1285) were used at indicated concentrations; the MOMP peptide 
was provided by Miles Inc.  (West Haven, CT).  Assays of the 
MOMP-specific T ceils included IL-2 at 30% of optimal levels for 
cell growth.  T cell stimulation was measured by [3H]thymidine 
incorporation: (cpm in the presence of antigen  -  cpm in the ab- 
sence of  antigen) or, for alloreactivity  (cpm in the presence of stimu- 
lators -  cpm in the absence of  stimulators). Data are median values 
from triplicate cultures from a representative experiment; SEM of 
relative responses (response to mutant/response  to 8.1.6) were <15% 
in two or more replicate experiments. 
Antibodies and Antibody Binding Assays.  mAbs  16.23, 7.3.1.9, 
NDS-9, and CD6.B1 react with polymorphic HLA-DR deter- 
minants, as indicated on Table 1. mAbs L243 and VI.15 react with 
monomorphic, conformational HLA-DR determinants, expressed 
on DR dimers. Exon-shuffled Eoe/DRce mutants map the L243 
determinant to the DRce chain (Chang, M.-d.Y., personal com- 
munication), mAb DA6.147 reacts with DRoe, both as a monomer 
and when associated with DILS. mAb B7/21.2 reacts with HLA- 
DP dimers and weakly with DPce and DRa monomers, mAb 
DA6.231 reacts with HLA-DR and -DP dimers and -DR and -DP 
fl chain monomers. Primary references  for these antibodies  are cited 
in reference 9, with the exceptions of NDS-9 (reference 25), L243 
(reference 26), and DA6.231 (reference 27). Cell surface radioim- 
mune binding was performed as described (17). Immunofluores- 
cence analysis was carried out using saturating amounts of unla- 
beled primary antibody,  followed  by fluoresceinated  goat anti-mouse 
IgG (H+L) (Tago Inc., Burlingame, CA). Staining with secondary 
antibody alone was used as a control for background fluorescence. 
Samples were analyzed on an EPlCS-C (Coulter Electronics, Inc., 
Hileah, Florida). 
Sequence AnalTsis.  Sequence analyses of the DRA and DRB 
genes of  8.1.6 and 10.24.6 were carried  out as described  (18). Briefly, 
cDNAs prepared from poly(A)  + RNA from 8.1.6 and 10.24.6 
were subjected  to PCR amplification  using DRA and DILB  primer 
pairs (see reference 18 for primer sequences). Size-selected  double- 
stranded PCR DNA was subjected to dideoxy sequencing using 
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Antibody binding ratio 
16.23  7.3.19 
anti-DR3  anti-DR3  NDS-9  CD6.B1  L243  VI. 15 
Cell line  DRw52  DRw52  anti-DR3  anti-DR3  anti-DR  anti-DR 
x  100 
8.1.6  100  100  100  100  100  100 
10.24.6  29  +  7  24  _+  5  21  +  4  115  +  3  62  _+  3  83  _+  1 
9.5.3  14  +  3  22  _+  2  11  _+  2  105  •  5  83  •  2  102  •  5 
10.24.6-DRA  73  •  4  ND  ND  ND  83  •  5  ND 
For 16.23, 7.3.19,  and VI.15,  binding ratio:  cpm bound by mutant  -  cpm bound by negative control/cpm bound by 8.1.6  -  cpm bound by 
negative control.  The negative control is 9.22.3,  a DR-null mutant derived from 8.1.6  (reference 17). The binding ratios for mutants  represent 
median values +  SEaM from three or more independent assays. For NDS-9, CD6.B1, and L243, data are derived from immunofluorescence analysis. 
Binding ratio: corrected mean channel fluorescence (linear scale) of mutant/corrected  mean channel fluorescence (linear scale) of 8.1.6.  Data were 
corrected for background  fluorescence assessed by binding of secondary antibody alone. The partial reconstitution  of 16.23 epitope expression in 
the 10.24.6-DtLA transfectant in all likelihood reflects continued expression of some mutant dimers in the transfectant. Some of the data on mutant 
9.5.3  have been reported  previously (9). 
modified T7 DNA polymerase (Sequenase; United States Biochem- 
ical Corp., Cleveland, OH). The PCR priraers and additional oli- 
gonucleotide primers covering 21-bp segments of the coding regions 
or their inverse complements were used to generate overlapping 
100-300 base segments of sequence information. The coding re- 
gion sequence of the DRB1 genes of mutant 10.24.6  and progen- 
itor, 8.1.6 are identical (Arp, B., unpublished data) and match the 
published DRB1  "0301  sequence (28). 
Western Blot Analysis and Dimer Stability Ability.  This assay has 
been described (17). Briefly, unboiled, whole-cell NP-40 extracts 
were analyzed by one-dimensional SDS-PAGE and immunoblotted 
with various antibodies:  anti-DR mAb DA6.147,  anti-DP mAb 
B7/21.2,  or anti-DR/DP mAb DA6.231.  For endoglycosidase F 
experiments, whole cell lysates were acetone precipitated, dissolved 
in 100 mM Tris-HC1, pH 8.0, 0.5%  SDS,  10%  2-ME,  10 mM 
EDrA, and boiled for 3 min. NP-40 was added to a concentration 
of 1%,  and samples were incubated for 1.5 h  at 37~  with or 
without 1.5/~1 of 50 U/m1 endoglycosidase F (Boehringer Mann- 
heim Corp., Indianapolis, IN). Samples were analyzed on a 10% 
SDS-PAGE gel and immunoblotted with mAb DA6.147,  which 
recognizes DRop. 
Reconstitution of HLA-DR Dimer Stability in SDS Using Added 
Pept/d~  Dimer reconstitution  was carried out using published 
methods (29, 30), with modifications. Briefly,  107 cells from pro- 
genitor 8.1.6 and mutant 10.24.6 were hbeled for 6 h at 37~  with 
1.0 mCi [3SS]methionine  and chased for 18 h.  HLA-DR3 mole- 
cules were arfinlty purified using the I-ILA-DR-specific mAb L243 
(reference 26).  For incubation with peptide, aliquots of affinity- 
purified material were acidified  from pH 8.0 to 4.5 with  1.7/~1 
1 M acetic add, incubated for 3 h at 37~  with DR3-binding pep- 
tides (MOMP 251-265 or heat-shock protein 65 3-13), and neu- 
tralized with 1.4/~1 1 M Tris. Peptides were present at a final con- 
centration of 100/~M.  Boiled samples were heated to 100~  for 
5 min. All samples were analyzed by nonreducing SDS-PAGE dec- 
trophoresis. 
Ion Exchange-HPLC and Sequence Analysis of  HLA-DR-associated 
Apt/des.  109 cells  from  the progenitor line 8.1.6  and  mutants 
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10.24.6  and 9.5.3 were lysed for 60 min at 4~  in 0.01  M  Tris, 
0.15  M  NaC1,  pH  7.4,  containing  the  detergent  polyoxyethy- 
lene-9-1aury!  ether and proteinase inhibitors (0.1  mM N-tosyl-L- 
lysine chloromethyl ketone, 0.5 mM phenylmethylsulphonyl fluo- 
ride, 0.5 mM iodoacetamide and 10 #g/ml aprotinin). HLA-DR3 
molecules were purified from chrified cell lysates by immunoaffinity 
chromatography using the HLA-DR-specific mAb L243 (reference 
26) and concentrated on a Centripep-30 (Amicon, Beverly, MA). 
Protein yields were estimated by gel filtration. The affinity-purified 
HLA-DR3 (400/~g) was ethanol-precipitated, dissolved in 0.1% 
trifluoroacetic acid in 20% acetonitrile, and incubated at 37~  for 
2.5 h. Peptides were separated by ion exchange chromatography 
on a Mono-S HR5/5 column (Waters Associates,  Milford, MA). 
The following ehtion buffers were used: buffer A (0.1% TFA in 
20% acetonitrile); buffer B (1 M NaC1 in buffer A). The column 
was equilibrated in buffer A and the peptides were eluted with a 
gradient of 0-100% buffer B from 5-60 min at a flow rate of 0.5 
ml/min. Injection volume was 200/~1.  Peptides  were detected by 
monitoring the absorbance at 214 nm. The material in the major 
peaks was further purified on an Aquapore RP300 reverse phase 
column (100  x  2.1 mm) using a 1040A HPLC system with a gra- 
dient of 10-40%  acetonitrile in 0.1%  TFA in water from 0-30 
min at a flow rate of 0.1 ml/min (both from Applied Biosystems 
Inc., Foster City, CA). Peptides present in each fraction were de- 
termined by NHz-terminal Edman sequencing and mass spectrom- 
etry. FOr clarity the variants differing only by the number of oxi- 
dized methionines are not shown. 
Results 
Mutant 10.24.6 Expresses an Altered DR~x Chain.  In an 
effort to isolate tones with single amino acid substitutions 
in the HLA-DR3 molecule, we chemically mutagenized pro- 
genitor 8.1.6, an HLA-DP,/DQ hemizygous, DR3-expressing 
B-LCL, and selected mutant derivatives that had lost binding 
of a DR3-specific antibody, 16.23 (see Materials and Methods). A 
92  93  94  95 
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8.1.6  L  T  N  S 
(progenitor) 
10.24.6  L  T  N  S 
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Figure  1.  (A) Locations of the 10.24.6 mutation and the resulting car- 
bohydrate addition site on a schematic representation of the HLA-A2 struc- 
ture. The structure of the MHC class I molecule,  HLA-A2 (heavy chain 
and 82-microglobulin) is shown to approximate the structure of the folded 
HLA-DR molecule, which shares structural features with MHC class I 
molecules (13, 14). The transmembrane regions of DRr~ and 8  are not 
shown.  Carbohydrate adduct is indicated as a branched chain, but is not 
drawn to scale. (ol96...  8118) is a predicted van der Waals contact; in 
the crystal structure of HLA-DR1, the relative Positions of the o~2 and 
82 domains are shifted compared to the corresponding domains of HLA- 
A2, allowing contact between side chains of o~96 and 8118 (14). This ~/8 
contact, which is likely conserved in HLA-DR3 molecules,  may be dis- 
rupted by the 10.24.6 DRA mutation, however, r~/8 dimers are nonethe- 
less formed (see text and Table 1). (b) Amino-add sequence (single-letter 
code) of residues 92-98 Of  DRA from mutant 10.24.6 and progenitor 8.1.6. 
The 10.24.6 mutation (C---~T) at codon 96 is shown. 8.1.6 sequence in 
this region is identical to published DRA sequence (47). N-linked glyco- 
sylation sequence is underlined. 
Immunoselection with mAb 16.23 yielded several types of 
mutants, including antigen presentation mutants altered at 
the MHC-linked, C2P-1 gene (9, 17, 18). The focus of this 
report is a unique,  16.23-selected  mutant,  10.24.6,  which 
harbors a point mutation in its single copy of the nonpolymor- 
phic DRA gene. The 10.24.6 mutation results in a Pro-~Ser 
substitution at position 96 in the DRc~2 domain (Fig. 1, A 
and B).  In addition, the mutation introduces an N-linked 
glycosylation sequence (Asn-X-Ser),  which directs carboby- 
&ate addition at residue 94N (Fig. 1, A and B). DKcx chains 
in 10.24.6 are indeed modified  by an extra N-linked carbohy- 
drate moiety; they are ~3 kD higher in apparent molecular 
mass than DRcx chains of progenitor 8.1.6 (Fig.  2, A  and 
B) and this molecular weight disparity is abolished when DRc~ 
chains of 10.24.6 and 8.1.6 are treated with endoglycosidase 
F, which removes N-linked sugars  (Fig.  2 A). 
The Mutant HLA-DR Heterodimers  Are Expressed  at Normal 
Levels, but Have Altered Conformation.  To determine the level 
of call surface expression of the mutant HLA-DR3 mole- 
cules, we measured  binding to 10.24.6 calls of a panel of DR3- 
reactive mAbs. 10.24.6 cells bind several antibodies at levels 
comparable to progenitor 8.1.6 (Table 1, antibodies CD6.B1, 
VI.15), indicating normal or near normal surface abundance 
of the mutant DR3 dimers. The formation of HLA-DR c~/~ 
dimers in 10.24.6 implies integrity of the pairing interactions 
known to occur within the oll/~1 domain of class II dimers 
(31, 32)  and argues  against the possibility that substantial 
structural changes are propagated from the site of the c~2 do- 
main mutation. However, the HLA-DR3 molecules expressed 
by 10.24.6 have lost binding of some antibodies (Table 1; an- 
tibodies 16.23, 7.3.19, NDS-9) specific  for polymorphic  (DRB) 
determinants that map to the peptide binding (al/B1) do- 
main (33, 34), implying altered conformation in this domain. 
The altered binding of these antibodies is a consequence of 
the DRA mutation, as 10.24.6 ceils transfected with a wild 
type DRA cDNA (10.24.6-DRA)  regain expression of a rele- 
vant epitope (Table 1; mAb 16.23); the L243 (DRc~) deter- 
Figure  2.  (A  ) HLA-DRot chains of mutant 
10.24.6 are modified  by an additional, N-linked 
carbohydrat~ Western blot analysis of boiled 
detergent (NIZ40) emracts of 10.24.6 and 8.1.6, 
with or without endoglycosidase treatment F 
(which removes N-linked carbohydrate).  Un- 
treated and endo F-treated samples were ana- 
lyzed by one-dimensioml SDS-PAGE and hn- 
munoblotted with mAb DA6.147, which reacts 
with DRc~ monomers. (/3) HLA-DR, but not 
-DP dimen extracted  from mutant 10.24.6 dis- 
sociate into monomefic subunits/n one-dimen- 
sional SDS-PAGE. Westea'n  blot analysis of de- 
tergent (N~0) ~tracts of indicated  cell  lines: 
10.24.6, DRA point mutant; mutants 9.5.3, 9.10.3, and 10.53.6,  8.1.6-derived C2P-1 presentation mutants (reference 9 and E. Mdlins, unpublished 
data);  9.22.3, 8.1.6-derived  DR-null mutant, which ~presses HLA-DQ and FILA-DP molecules  (17); 8.1.6,  progenitor line.  Unboiled, whole-cell 
~tracts were analyzed by oneMimemional SDS-PAGE and immunoblotted with anti-DR mAb DA6.147 (kfi); or with anti-DP mAb B7/21.2 (m/ddk); 
or with anti-DR and -DP mAb DA6.231  (right). Because B7/21.2 reacts  only weakly with monomers, the altered stability of the DP molr  in 
mutant 9.5.3 is best evaluated by the disappearance of DP dime, (lane 4, m/rid/e).  DR-null mutant 9.22.3 is indoded as a control for antibody spcciticity; 
as expected,  the dim~ band from 9.22.3  is equivalent  in intensity to that of 8.1.6 with the anti-DP antibody (m/rid/e)  but of lower intensity than 
that of 8.1.6 with antibody that recognizes both DR. and DP molecules  (right). FILA-DP dimen of 10.24.6 appear unaffected by the 10.24.6 DRA 
mutation, as ~tpected, since DR~x/DP8 dimers are ~pressed infrequently,  if at all, in these cells (E.  Mellins, unpublished results). 
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Of interest, the pattern of binding of anti-DR3 antibodies 
to mutant 10.24.6 resembles that observed with the 8.1.6- 
derived C2P-1 mutants, which have wild type DRA and B 
gene sequences, but are deficient in intracellular formation 
of peptide/class II molecule complexes (e.g.,  mutant 9.5.3, 
Table 1). These results suggest that the DR molecules of 
10.24.6 and those of C2P-1 mutants have similar changes in 
conformation at their peptide binding domains. 
The Mutant HLA-DR Dimers Are Unstable in SDS Deter- 
gent.  To further assess the structure of class II molecules 
in mutant 10.24.6, we utilized an assay of class II dimer sta- 
bility. Stability in SDS detergent solutions is a characteristic 
of a proportion of the mature class II molecules that have 
bound peptide (29, 35-37); class II dimers of C2P-1 mutants, 
on the other hand, are unstable in SDS (9).  As shown in 
Fig.  2 B, the vast majority of HLA-DR dimers extracted 
from mutant 10.24.6 resemble those from C2P-1  mutants 
(e.g.,  9.5.3, 9.10.3,  10.53.6) and dissociate into monomers 
in SDS-PAGE. However, the HLA-DP dimers of 10.24.6 and 
progenitor 8.1.6 maintain stability in SDS, unlike HLA-DP 
dimers in C2P-1 mutants (Fig. 2 B, middle and right). The 
SDS instability of the mutant DR molecules in 10.24.6 indi- 
cates that these molecules are altered in conformation com- 
pared to the majority of the HLA-DR molecules in the pro- 
genitor cell; the fact that SDS instability is limited to HLA-DR 
molecules in 10.24.6 implies that this phenotype results from 
mutation of the DRA gene. 
We considered several mechanisms that might be the basis 
of the SDS unstable phenotype of HLA-DR dimers in mu- 
tant 10.24.6.  SDS instability is observed in nascent class II 
molecules before dissociation of Ii chain (36),  and in class 
II molecules (e.g., I-A  k) synthesized in the absence of invar- 
iant chain (38). However, neither lack of nor prolonged as- 
sociation with intact invariant chains explains the SDS insta- 
bility of the HLA-DR molecules of 10.24.6, as the kinetics 
of Ii association and dissociation from the mutant DR mole- 
cules are normal (Amaya, M., and E. Mellins, data not shown). 
SDS instability is also a feature of class II molecules that lack 
immunogenic  peptides, such as insect cell-derived HI.A-DR1 
molecules devoid of peptides (39), and class II molecules of 
C2P-1  mutants,  which  are  defective  in  generating  pep- 
tide/MHC class II complexes. To determine whether altered 
peptide loading is the basis of SDS instability in the HLA- 
DR molecules of 10.24.6, we first used antigen presentation 
to class II-restricted T ceils to assess formation of class II/pep- 
tide complexes from endocytosed proteins. Fig.  3 a  shows 
a comparison of T  cell stimulation by 10.24.6 and progen- 
itor 8.1.6.  When provided with intact protein as antigen, 
the 10.24.6 mutant is unable to stimulate DR3-restricted T 
ceils. An allospecific anti-DR3 T ceil done whose reactivity 
is apparently peptide dependent (24) is also nonresponsive 
to 10.24.6 cells. In contrast, T cells restricted by the appro- 
priate HLA-DQ and -DP alleles readily respond to 10.24.6 
cells as antigen presenting cells. These results indicate that 
generation of peptide/HLA-DR complexes is impaired in 
10.24.6. The DRospecific defect in mutant 10.24.6 cells reflects 
exclusion of the mutant DR molecules from participation 
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in the peptide-loading pathway, rather than the absence of 
a DR-specific accessory factor, since the 10.24.6-DRA trans- 
fectant regains the ability to stimulate DR3-restricted T ceils 
(Hg.  3 a), whereas a somatic cell hybrid between 10.24.6 
and a homozygous DRA deletion mutant (10.24.6  x  9.22.3) 
maintains the mutant phenotype (Fig.  3 a). 
Mutant HLA-DR Molecules in I0.24.6 Bind DR-restricted 
tides.  It  was possible  that  the mutant DR  molecules in 
10.24.6 were unable to participate in the normal process of 
peptide loading because their altered structure rendered them 
unable to bind peptides. To evaluate this possibility, we first 
tested the ability of 10.24.6 cells to stimulate DR-restricted 
T ceils with peptide antigen. As shown in Fig. 3 b, HLA-DR 
molecules expressed by 10.24.6 present two DR-restricted 
peptides, one from the MOMP of C. trachomatis (241-265) 
(Barbosa, J., manuscript submitted for publication) and one 
from TT (1274-1285) (reference 40).  These results indicate 
binding of immunogenic  peptides to DR molecules of 10.24.6, 
however, they leave open the possibility that only a small frac- 
tion of 10.24.6 DR molecules, sufficient for T ceU stimula- 
tion (41), is capable of binding peptide. We therefore uti- 
lized  an  assay in  which  peptide binding  to  the  mutant 
molecules was detected by reconstitution of SDS-stable dimers 
(29,  30). In the absence of added peptide, DR3 molecules 
affinity purified from mutant 10.24.6 dissociate  into monomers 
in SDS without boiling, whereas DR3 molecules affinity 
purified from progenitor 8.1.6 maintain the dimeric state in 
SDS, unless boiled (Fig. 4). After incubation at pH 4.5 with 
either of two DR3-restricted peptides (MOMP  [251-265] 
or mycobacterial heat-shock protein 65 [3-13] [reference 42]), 
a majority of the affinity purified DR molecules from 10.24.6 
forms SDS stable dimers, implying they have bound peptide 
(Fig. 4). These results,  together with the peptide presenta- 
tion assays, indicate that the structural changes and functional 
defects in the DR molecules of 10.24.6 are unlikely to derive 
from an intrinsic inability of the mutant molecules to bind 
immunogenic peptides. 
HLA-DR Molecules in Mutant 10.24.6 and in C2P-1 Mutant 
9.5.3 Are Associated with Invariant Chain Peptides.  The SDS 
instability of HLA-DR3 molecules in mutant 10.24.6 thus 
appears to reflect a defect in the loading of these molecules 
with naturally processed peptides. To directly evaluate pep- 
tide occupancy of DR molecules in 10.24.6, we affinity purified 
HLA-DRcffB dimers, extracted the associated peptides, and 
analyzed the peptides by ion exchange and reverse  phase HPLC. 
Further, as the antibody binding profile,  dimer instability, 
and antigen presentation defects of the HLA-DR3 molecules 
of 10.24.6 mimicked those of the DR3 molecules of C2P-1 
presentation mutants, we compared the profiles of peptides 
eluted from the DR3 molecules of 10.24.6 to those eluted 
from 9.5.3, a representative  C2P-1 mutant. Fig. 5 a shows 
the chromatograms of HLA-DR3-assodated peptides from 
mutants 10.24.6,  9.5.3, and progenitor 8.1.6.  Based on in- 
tegration of the A2t4 trace of these chromatograms, mutant 
and progenitor-derived  DR3 yielded similar amounts of total 
peptides per mole of protein (70-85% of the starting amount). 
However, the profiles of peptides extracted from HLA-DR3 
molecules of the two mutants contain a set of prominent peaks a 
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Figure 3.  (a) HLA class II-restricted 
presentation of  endocytosed,  native  pro- 
tein antigens by mutant 10.24.6, pro- 
genitor 8.1.6, hybrid 10.24.6 x 9.22.3, 
or transfectant 10.24.6-DRA  as antigen- 
presenting cells. T cells are designated 
by antigen and restricting element and 
include four  antigen-specific T  cell 
tones (specific  for PPD, TT, HBsAg), 
2 alloreactive  T cell clones (specific  for 
DIL3B1  [DR17] and DQ2), an alloreac- 
tive, anti-DP4 T cell line and a class II- 
restricted polyclonal  T cell line specific 
for TT. The PPD-specific  clones differ 
in fine specificity (18). The three TT- 
specific lines shown were derived from 
different donors. The stimulation  of  the 
TT-specific, class ll-restricted T cell line 
by mutant  10.24.6 likely reflects pri- 
marily DQ- or DP-restricted presenta- 
tion,  as  "~90% of the  response to 
10.24.6 was observ~ using the DR-null 
mutant  9.22.3 as  antigen-presenting 
cells (E. Mellins, data not shown). (b) 
Proliferation of  MOMP-specific  and TT- 
specific  DR-restricted T cells stimulated 
with immunogenic  peptides, presented 
by mutant  10.24.6, DR-null mutant 
9.22.3, or progenitor 8.1.6. MOMP 
241-265 in association with  DR3/31 
stimulates  a  MOMP-specific T  cell 
clone. The peptide corresponding to 
residues 1274-1285  of  TT in association 
with DtL3B3 stimulates a subset of T 
cells within  the polyclonal, class II- 
restricted TT-specific  T cell line; stim- 
ulation of this line with native TT is 
shown in a (TT/class II). 
Figure  4.  Mutant  HLA-DR 
molecules bind  antigenic  pep- 
tide  and  regain SDS  stability. 
HLA-DK molecules  were ai~nity 
purified  from  metabolically- 
labeled (6-h pulse/18-h chase) pro- 
genitor 8.1.6 and mutant 10.24.6 
cells. DR molecules were treated 
as  indicated (see Materials and 
Methods for details) and analyzed 
by SDS-PAGE.  The bands in the 
dimer region of the boiled 8.1.6 
sample and the  non-boiled and 
boiled 10.24.6 samples likely  reflect the "floppy"  dimer  conformation,  which 
runs at a higher apparent molecular weight in SDS-PAGE (29). 
that  are present  at  most in trace amounts  in  the eluate  of 
the progenitor cells. We identified the peptides corresponding 
to  these  peaks by a  combination of NHz-terminal  Edman 
degradation and mass spectrometry after further purification 
by reverse phase HPLC.  As  shown in Fig.  5  b,  the DK3- 
associated peptides from the mutants derive from a common 
region of the invariant chain (residues  80-103).  Using A214 
absorbance, we estimated that at least 60%  of the total iso- 
lated peptides from both 10.24.6 and 9.5.3 was derived from 
Ii. None of the same peptides was detectable by reverse phase 
chromatography or mass spectrometry in the ehate from 8.1.6 
cells (Cameron, P., unpublished results). The observation that 
HLA-DK3 molecules from mutants  10.24.6  and 9.5.3  are 
associated with the same Ii-derived peptides reveals  the struc- 
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Figure 5.  (a) Ion exchange-HPI.C profiles of HLA-DR3-associated pep- 
tides from mutants and wild type cell  lines. Upper chromatogram  (8.1.6) 
represents  the profile  obtained  from the HLA-DR  hemizygous  progenitor 
cells. Middle (10.24.6) and bottom (9.5.3) chromatograms  represent  the 
HLA-DR3-associated  peptides  from mutant cells. (b) Sequences  of HLA- 
DR3-associated  invariant  chain  peptides. The numbers  above  the sequences 
refer to the amino acid positions within the invariant chain; residues are 
numbered from NH2 terminus of p33 form of Ii. 
rural basis for their similar phenotypes and confirms that in 
both mutants HLA-DR molecules fail to mature to appropri- 
ately loaded species. 
Discussion 
In mutant 10.24.6, striking alterations in the structure and 
antigen presentation function of the HLA-DR molecule are 
associated  with a point mutation in the DRA  gene. The 
phenotype of the mutant molecules can be specifically attrib- 
uted to the DRA mutation, as transfection of 10.24.6  cells 
with a wild type DRA gene restores the wild type pheno- 
type (Table 1 and Fig. 3). The mutation results in two struc- 
tural changes in the DRot chain: (a) loss of a proline residue, 
96P, which is highly conserved in murine and human class 
II o~ chains (43) and likely interacts with a conserved ~ chain 
residue (Fig.  1 a); and (b) addition of a bulky carbohydrate 
adduct to the o~2 domain. The latter effect of the mutation 
may be more critical for the phenotype of the molecules be- 
cause the particular amino acid substitution in DRoL, serine 
for proline,  is a relatively conservative change (44). 
The key features of the DR molecules expressed by the 
10.24.6  mutant, loss of expression of certain antibody epi- 
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topes, altered stability in SDS detergent solution, and deficient 
DR-restricted presentation of endocytosed protein, but not 
peptide, suggest a defect in formation of complexes between 
DR molecules and naturally processed peptides. In this re- 
port, we demonstrate that the mutant molecules are predom- 
inantly associated with peptides derived from Ii  (residues 
80-103), and are in this regard similar to DR molecules of 
antigen presentation mutants with defects in an MHC-linked 
gene(s) (Fig.  5,  and references 30,  45).  Fragments derived 
from the same region of invariant chain have also been found 
in association with several class II alleles in both human and 
murine wild type cells (1, 2, 46). The Ii-derived peptides may 
represent products of Ii proteolysis that reassociate with class 
II molecules (in competition with available immunogenic pep- 
tides) or they may be residual fragments of Ii that require 
removal to allow binding of immunogenic peptides. The DR 
eluates from both mutant 10.24.6 and the C2P-1 mutant 9.5.3 
also contain non-Ii peptides, but these have not yet been charac- 
terized. Analysis of these non-Ii peptides may also shed light 
on the nature of the defect(s) in the two mutant cells. 
Mutant 10.24.6  is unique in having a defined genetic le- 
sion in DRA that yields HLA-DR molecules predominantly 
associated with Ii-derived peptides. Several mechanisms may 
be envisioned to account for this phenotype in 10.24.6 cells. 
(a) The mutant DR molecules have increased affinity for Ii- 
derived peptides. While this alternative can not be ex_cluded, 
carbohydrate addition to DRo~ is more likely to introduce 
steric inhibition of a critical interaction than to enhance affinity 
for an associated peptide. (b) The DRA mutation alters traf- 
ficking of DR molecules such that they do not encounter 
immunogenic peptides.  The mutant molecules are known 
to arrive at a peripheral endocytic compartment where Ii pro- 
teolysis is accomplished; however, peptide loading may re- 
quire transport to another compartment. This transport may 
be mediated by a non-Ii chaperone, which does not recog- 
nize the mutant DR molecules. Alternatively, transport of 
DR molecules may require homotypic aggregation, which 
is blocked in the mutant molecules. Homotypic interaction 
between HLA-DR1 molecules occurs during crystallization 
(reference 14), and the resulting dimer of dimers includes an 
interface near the region of DRol altered by aberrant glyco- 
sylation in 10.24.6.  (c) The DR molecules in 10.24.6  reach 
the appropriate subcdlular location but are unable to partici- 
pate in the peptide-loading process.  The mutant molecules 
are capable of binding and presenting extracellular peptides. 
However, physiologic formation HLA-DR/peptide complexes 
may involve an accessory molecule that either removes Ii frag- 
ments or loads immunogenic peptides. The altered DRot chain 
in  10.24.6  could hinder the binding or activity of such a 
molecule. 
In several of the mechanisms proposed to account for the 
10.24.6 phenotype, interaction between the HLA-DR mol- 
ecule and a non-Ii accessory molecule is postulated. Antigen 
presentation mutants with defects in the MHC-linked C2P-1 
gene provide evidence for such a non-Ii accessory molecule 
and indicate its critical function in the generation of pep- 
tide/class II molecule complexes. Indeed, as mutation of the 
C2P-1 gene and the DRA gene both generate HLA-DR tool- ecules with similar characteristics,  it is attractive to speculate 
that direct association between class II molecules and the C2P-1 
protein occurs during normal dass II molecule biosynthesis 
and that the region of the class II c~ chain affected by the 
10.24.6  mutation mediates this interaction. 
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